Humatrope ® (somatropin (rDNA ursprung) för injektion)

För fullständig produktresumé för Humatrope® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

HUMATROPE® (somatropin): Användning hos patienter med COVID-19 (coronavirus disease 2019)

Användningen av somatropin hos patienter med COVID-19 har inte studerats.

Use of Humatrope (somatropin) in a Patient With COVID-19

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of Humatrope in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure. 2

Dyspnoea has been reported in somatropin clinical trials and post-marketing spontaneous reports in 1%-10% of adults.2

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with Humatrope who has confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Humatrope [summary of product characteristics]. Eli Lilly and Company Limited, Hampshire.

3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

4. COVID-19 INFORMATION FOR CHILDREN AND ADOLESCENTS LIVING WITH ENDOCRINE CONDITIONS, INCLUDING TYPE 1 DIABETES MELLITUS https://www.eurospe.org/news/item/14064/COVID-19-information-for-children-and-adolescents-living-with-endocrine-conditions-including-type-1-diabetes-mellitus Accessed March 26, 2020

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

COVID-19 = coronavirus disease 2019

ECDC = European Centre for Disease Prevention and Control

ESPE = European Society for Paediatric Endocrinology

EU WHO = World Health Organization (European regional office)

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Datum fӧr senaste ӧversyn 2020 M03 17

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss